India, May 13 -- Personalis, Inc. (PSNL) announced that Medicare has expanded coverage for its NeXT Personal minimal residual disease (MRD) test, allowing late-stage solid tumor patients receiving immunotherapy to access ultrasensitive molecular monitoring. This expansion was issued through the Centers for Medicare & Medicaid Services' MolDX program.
The decision is supported by clinical evidence generated with the Vall d'Hebron Institute of Oncology (VHIO).
The newly published VHIO study showed that NeXT Personal's ultrasensitivity enables physicians to track tumor dynamics, evaluate treatment response and predict clinical outcomes during immunotherapy.
The study showed that NeXT Personal can track tumor dynamics and identify molecular ...